

Melanoma

Ipilimumab
monotherapy

Nivolumab 2nd-line
Pembrolizumab 2nd-line

Nivolumab 1st-line
Ipilimumab adjuvant
Nivolumab +
Ipilimumab combo

Pembrolizumab 1st-line

Nivolumab
PD-L1 IHC Assay

2011

2012

2013

2014

2015

2016

2017

Non-Melanoma

Nivolumab
Sq. NSCLC 2nd-line

Pembrolizumab
NSCLC 2nd-line
PD-L1 IHC Assay

Nivolumab
Non-Sq NSCLC 2nd-line
PD-L1 IHC Assay

Nivolumab
RCC 2nd-line

Atezolizumab
Bladder 2nd-line
PD-L1 IHC Assay

Nivolumab
Hodgkin lymphoma
3rd-line

Pembrolizumab
HNSCC 2nd-line

Atezolizumab
NSCLC 2nd-line

Pembrolizumab
NSCLC 1st-line
PD-L1 IHC Assay

Nivolumab
HNSCC 2nd-line

Nivolumab
Bladder 2nd-line

Pembrolizumab
Hodgkin
lymphoma
4th-line

Avelumab
MCC 1st-line

Pembrolizumab
MSI-H, dMMR tumors
2nd-line

Durvalumab
Bladder 2nd-line
PD-L1 IHC Assay

Pembrolizumab
+ pemetrexed
and carboplatin
NSCLC 1st-line

Avelumab
Bladder 2nd-line